Linking Oncology Diagnostic Labs to Assess their Effectiveness in Supporting Immunotherapy Treatment Selection in Lung Cancer

A molecular diagnostics company developed a blood test to support treatment selection for patients with advanced non-small cell lung cancer (NSCLC). While many patients with EGFR-mutated, PDL-1 expressing NSCLC respond to immune checkpoint inhibitors (ICIS), many do not. An unmet medical need existed for a more precise test to determine which patients with this tumor type would respond to ICIS. The client’s blood test purported to predict patient response to ICIS.